Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104603 | 0.90 | ATM (0.54) | ATMMEN1KMT2APOLBCACNA1B | |
| SCHEMBL905973 | 0.85 | ATM (0.59) | ATMMEN1KMT2APOLBCACNA1B | |
| SCHEMBL19691980 | 0.85 | ATM (0.59) | ATMMEN1KMT2APOLBCACNA1B | |
| SCHEMBL1104570 | 0.82 | ATM (0.39) | ATMMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL16358149 | 0.82 | ATM (0.39) | ATMMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL1104598 | 0.81 | ATM (0.51) | ATMMEN1KMT2APOLBCACNA1B | |
| SCHEMBL1104567 | 0.78 | ATM (0.40) | ATMMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL13325754 | 0.77 | ATM (0.39) | ATMMEN1KMT2APOLBCACNA1B | |
| SCHEMBL19102097 | 0.77 | KMT2A (0.41) | ATMMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL15085996 | 0.76 | ATM (0.59) | ATMMEN1KMT2APOLBCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | ATM 3498/4885MEN1 1388/4885KMT2A 2924/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | ATM 3498/4885MEN1 1388/4885KMT2A 2924/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | ATM 3498/4885MEN1 1388/4885KMT2A 2924/4885 |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | ATM 3498/4885MEN1 1388/4885KMT2A 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.